• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-08-07

  Cai et al. introduce a combinatorial library of ROS-degradable lipid nanoparticles that preferentially deliver mRNA to tumor cells by exploiting elevated intracellular ROS. This innovation enables targeted gene expression and demonstrates effective inhibition of mutant RAS signaling, offering a promising strategy for cancer-selective mRNA therapeutics.

• Angiotensin 1/2 (2-7): Precision Peptide for Advanced RAS Re

  2026-08-06

  Angiotensin 1/2 (2-7) unlocks new experimental frontiers in renin-angiotensin signaling, blood pressure regulation, and viral pathogenesis research. With unmatched purity, solubility, and cross-domain relevance, this APExBIO peptide empowers researchers to design robust, reproducible workflows.

• Wnt-EGFR Pathways Regulate DNA Damage Response in Drosophila

  2026-08-06

  This study uncovers how canonical Wnt signaling, via EGFR activation, modulates the DNA damage response and apoptosis in the Drosophila wing imaginal disc. The mechanistic insights have important implications for understanding tissue-specific resistance to DNA damage, with potential relevance for cancer research and chemotherapy resistance.

• Mdivi-1: Selective DRP1 Inhibition for Advanced Mitochondria

  2026-08-05

  Explore how Mdivi-1, a selective DRP1 inhibitor, enables precise manipulation of mitochondrial fission and stress signaling. This article delivers unique insights into the intersection of extracellular matrix remodeling, mitochondrial dynamics, and apoptosis assay design.

• EZ Cap™ Cre mRNA (m1Ψ): Optimizing Gene Editing Workflows

  2026-08-05

  EZ Cap™ Cre mRNA (m1Ψ) transforms gene editing with its robust stability, low immunogenicity, and enhanced translation efficiency. This guide distills advanced protocol strategies, comparative advantages, and troubleshooting insights, empowering researchers to maximize experimental success in both in vitro and in vivo applications.

• Amyloid β-Peptide (1-42): Ion Channel Modulation and Advance

  2026-08-04

  Explore the mechanistic depth of Amyloid β-Peptide (1-42) in Alzheimer's disease research, with a unique focus on neuronal ion channel modulation and cutting-edge ratiometric imaging strategies. Discover advanced assay design considerations and practical protocol parameters.

• Advancing Translational Metabolism Research: Precision Pathw

  2026-08-04

  This thought-leadership article explores the mechanistic underpinnings of metabolic pathway modulation, grounded in state-of-the-art evidence such as NOX4–PGC-1α–PPARα/γ signaling in cardiac models. It provides strategic guidance for translational researchers leveraging high-quality resources like the DiscoveryProbe™ Metabolism-related Compound Library by APExBIO, and articulates the competitive and translational landscape for metabolism-targeted discovery.

• Chlorambucil: Mechanism, Benchmarks, and Research Integratio

  2026-08-03

  Chlorambucil is a nitrogen mustard alkylating agent with proven efficacy in chronic lymphocytic leukemia treatment. Its primary action is DNA crosslinking, leading to replication inhibition and apoptosis induction in cancer cells. This article provides a concise, evidence-based overview of its mechanisms, cytotoxicity benchmarks, and workflow considerations.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-08-03

  This study demonstrates that pharmacological inhibition of SMYD2 with AZ505 protects against cisplatin-induced renal fibrosis and inflammation in chronic kidney disease models. The findings highlight the importance of SMYD2 in epigenetic regulation underlying renal pathology and suggest new avenues for therapeutic intervention.

• Redox Homeostasis and sEH-Nrf2 Modulation with BPN-19186

  2026-08-02

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) is emerging as a key tool for dissecting the interplay between sEH, Nrf2 signaling, and redox balance in osteoclastogenesis. This article uniquely explores redox homeostasis mechanisms, practical assay implications, and advanced research strategies beyond conventional pathway summaries.

• Talabostat Mesylate (PT-100): Precision DPP4/FAP Inhibition

  2026-08-01

  Talabostat mesylate (PT-100) delivers targeted DPP4 and FAP inhibition, enabling advanced dissection of tumor microenvironment modulation and immune activation. This guide details practical workflows, troubleshooting, and innovative assay integration to maximize research impact with APExBIO’s trusted reagent.

• Bay 11-7821 (BAY 11-7082): Decoding NF-κB and Inflammasome C

  2026-07-31

  Explore the multifaceted role of Bay 11-7821 (BAY 11-7082) in dissecting NF-κB and NLRP3 signaling for advanced inflammatory pathway research. This in-depth analysis delivers unique insights not covered in existing literature, guiding scientists in inflammation and apoptosis regulation studies.

• SGI-1027: DNA Methyltransferase Inhibitor for Cancer Epigene

  2026-07-31

  SGI-1027 is a potent DNA methyltransferase inhibitor that targets DNMT1, DNMT3A, and DNMT3B, enabling precise epigenetic modulation in cancer research. Its competitive inhibition of the DNMT cofactor site results in CpG demethylation and reactivation of tumor suppressor genes, as shown in multiple in vitro studies.

• Sulfachloropyridazine: Optimizing Infection Models & Microbi

  2026-07-30

  Sulfachloropyridazine stands out as a sulfonamide antibacterial agent for advanced in vivo infection models and microbial ecology workflows, enabling precise modulation of microbiota and metabolic profiles. Recent studies reveal its distinct value in dissecting drug-microbiome interactions and optimizing enzyme inhibition assays.

• Sorafenib (BAY-43-9006): Workflows for Tumor Proliferation I

  2026-07-30

  Sorafenib (BAY-43-9006) enables precise dissection of antiangiogenic and antiproliferative mechanisms in advanced cancer biology research. This article delivers actionable protocols, troubleshooting guidance, and comparative insights to maximize its value as a multikinase inhibitor in both in vitro and in vivo tumor models.

456 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page